|1.||Frey, Brigitte M: 11 articles (01/2014 - 05/2003)|
|2.||Frey, Felix J: 10 articles (01/2014 - 05/2003)|
|3.||Stewart, Paul M: 10 articles (06/2009 - 01/2002)|
|4.||Seckl, Jonathan R: 7 articles (01/2009 - 08/2003)|
|5.||Sasano, Hironobu: 7 articles (01/2008 - 11/2002)|
|6.||Frey, F J: 7 articles (06/2002 - 03/2000)|
|7.||Suzuki, Takashi: 6 articles (12/2005 - 11/2002)|
|8.||Stewart, P M: 6 articles (03/2004 - 01/2001)|
|9.||Dick, Bernhard: 5 articles (02/2009 - 05/2003)|
|10.||Frey, B M: 5 articles (06/2002 - 10/2000)|
|1.||Hypertension (High Blood Pressure)
04/01/1999 - "Finally, while some studies demonstrate impaired 11beta-HSD activity in broader populations of patients with hypertension, further studies are required to clarify the role of 11beta-HSD2 in 'essential' hypertension."
12/01/1997 - "Further studies are now required in order to evaluate the role of 11beta-HSD2 activity in the pathophysiology of 'essential' hypertension."
06/01/2009 - "In conclusion, 19-nor-P did not inhibit human 11beta-HSD2 and seems not to be involved in human hypertension. "
06/01/2008 - "Reduced 11beta-HSD2 activity emerges as a previously unrecognized risk factor contributing to the rising prevalence of arterial hypertension in elderly. "
03/01/2008 - "It is well established that reduced 11beta-HSD2 activity causes hypertension and electrolyte abnormalities. "
|2.||Fetal Growth Retardation (Intrauterine Growth Retardation)
04/01/2000 - "In humans, 11beta-HSD2 gene mutations produce a low birthweight, and some studies show reduced placental 11beta-HSD2 activity in association with intrauterine growth retardation. "
06/01/2009 - "In conclusion, placental 11beta-HSD2 gene expression might predict postnatal growth in IUGR."
06/01/2009 - "Gene expression of 11beta-HSD2 at birth correlated positively with birth length (r = 0.55, p = 0.04) and inversely with growth velocity in the first year of life (r = -0.69, p = 0.01) in the IUGR, but not in the AGA group. "
02/01/2008 - "Taken together, our present findings provide evidence suggesting a role for an attenuated placental as well as fetal 11beta-HSD2 in the pathogenesis of IUGR."
02/01/2008 - "There is evidence that placental 11beta-HSD2 is reduced in pregnancies complicated with intrauterine growth restriction (IUGR), but the relationship between the two is uncertain owing to other maternal complications often associated with this pathological condition of pregnancy. "
06/01/2008 - "Our study indicates MR and 11beta-HSD2 are both sensitive and specific markers of the distal nephron and its related neoplasms (CHRCC and OC). "
06/01/2008 - "MR and 11beta-HSD2 should be considered in the immunohistochemical panel to more accurately subtype renal cell tumors."
06/01/2008 - "Our goal was to determine whether MR and 11beta-HSD2 expression could be used to characterize the major types of renal cell neoplasms. "
02/12/2004 - "The finding that 11-ketoDex is a specific GR agonist may explain the potent glucocorticoid effect of Dex in tissues expressing 11beta-HSD2 including kidney and colon and also in certain tumor cells."
03/20/2003 - "We propose that abnormal expression of 11 beta-HSD2 acts as a proproliferative prereceptor determinant of pituitary cell growth, and may provide a novel target for future tumor therapy."
04/01/2007 - "11beta-Hydroxysteroid dehydrogenase type 2 in pregnancy and preeclampsia."
11/01/2005 - "Recent reports suggest decreased placental 11beta-HSD2 activity in pregnancies complicated by preeclampsia. "
02/01/2009 - "In line with our hypothesis, reduced 11beta-HSD2 activity in preeclampsia is unable to abolish placental cortisol, a finding clearly associated with prematurity and low birth weight."
02/01/2009 - "In healthy pregnancies, the fetus is protected from high circulating cortisol levels by the placental 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2), which is reduced in preeclampsia. "
04/01/2007 - "Numerous signals such as proinflammatory cytokines known to be present and/or elevated in preeclampsia regulate 11beta-HSD2 activity. "
09/01/2003 - "The human choriocarcinoma cell line JEG-3, which expresses the 11beta-HSD2 isoenzyme, was used. "
04/01/1995 - "11 alpha-OHP and 11 beta-OHP were potent inhibitors of both 11 beta-HSD1 in rat liver microsomes and 11 beta-HSD2 in lysates of JEG-3 cells, a human choriocarcinoma cell line. "
07/01/1999 - "In the present study, we examined the effects of eicosanoids on the activity of 11beta-HSD2 in human choriocarcinoma JEG-3 cells, a well-established model for placental trophoblasts. "
07/01/2005 - "Effect of pro-inflammatory cytokines on expression and activity of 11beta-hydroxysteroid dehydrogenase type 2 in cultured human term placental trophoblast and human choriocarcinoma JEG-3 cells."
03/01/1999 - "Retinoic acid stimulates the expression of 11beta-hydroxysteroid dehydrogenase type 2 in human choriocarcinoma JEG-3 cells."
|2.||11-beta-Hydroxysteroid Dehydrogenase Type 1
|5.||Messenger RNA (mRNA)
|7.||Mineralocorticoid Receptors (Mineralocorticoid Receptor)
|8.||11-beta-Hydroxysteroid Dehydrogenase Type 2 (11 beta-Hydroxysteroid Dehydrogenase Type 2)
|9.||Glucocorticoid Receptors (Glucocorticoid Receptor)
|2.||Renal Dialysis (Hemodialysis)